Patent details

EP3419595 Title: STABLE LIQUID GONADOTROPIN FORMULATION

Basic Information

Publication number:
EP3419595
PCT Application Number:
EP2017054325
Type:
European Patent Granted for LU
Legal Status:
In force
Application number:
EP177075272
PCT Publication Number:
WO2017144659
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
STABLE LIQUID GONADOTROPIN FORMULATION
French Title of Invention:
FORMULATION LIQUIDE STABLE DE GONADOTROPHINES
German Title of Invention:
STABILE FLÜSSIGE GONADOTROPIN-FORMULIERUNG
SPC Number:

Dates

Filing date:
24/02/2017
Grant date:
06/01/2021
EP Publication Date:
02/01/2019
PCT Publication Date:
31/08/2017
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
06/01/2021
EP B1 Publication Date:
06/01/2021
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
Expiration date:
24/02/2037
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
30/12/2020
 
 

Name:
Ferring B.V.
Address:
Polaris Avenue 144, 2132 JX Hoofddorp, Netherlands (NL)

Agent

Name:
ARONOVA S.A.
From:
24/02/2021
Address:
PO Box 327, L-4004, ESCH-SUR-ALZETTE, Luxembourg (LU)
To:

Inventor

1

Name:
SJÖGREN, Helen Ulrika
Address:
Sweden (SE)

2

Name:
HØJER-PEDERSEN, Charlotte
Address:
Denmark (DK)

Priority

Priority Number:
201603280
Priority Date:
24/02/2016
Priority Country:
United Kingdom (GB)

Classification

IPC classification:
A61K 9/00; A61K 9/08; A61K 47/18;

Publication

European Patent Bulletin

Issue number:
202101
Publication date:
06/01/2021
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
02/03/2026
Annual Fee Number:
10
Annual Fee Amount:
131 Euro
Expected Payer:
Last Annual Fee Payment Date:
24/02/2025
Last Annual Fee Paid Number:
9
Last Annual Fee Paid Amount:
115 Euro
Payer:
IPAN GMBH
Filing date Document type Number of pages
24/02/2021 Power Of Attorney 1
03/03/2021 Outgoing Correspondence 1